vimarsana.com

Latest Breaking News On - Yonsei university college - Page 1 : vimarsana.com

Dr Cho on Amivantamab Plus Lazertinib in Atypical EGFR-Mutated NSCLC

Byoung Chol Cho, MD, PhD, discusses findings from the CHRYSALIS-2 trial of amivantamab plus lazertinib in patients with atypical EGFR-mutant NSCLC.

Byoung-chol-cho
Yonsei-university-college-of-medicine
Yonsei-cancer-center
Division-of-medical-oncology
Medical-oncology
Yonsei-university-college

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4.

Seoul
Soult-ukpyolsi
South-korea
Mannheim
Baden-wüberg
Germany
Ukraine
Russia
Texas
United-states
Hye-ryun-kim
Mary-beth-sandin

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Belgium
Hoboken
Region-flamande
Seoul
Soult-ukpyolsi
South-korea
Illinois
United-states
Chicago
Beerse
Singapore
American

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 - Affimed (NASDAQ:AFMD)

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab led to a disease control

Seoul
Soult-ukpyolsi
South-korea
Ukraine
Chicago
Illinois
United-states
Germany
Mannheim
Baden-wüberg
Texas
Russia

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Seoul
Soult-ukpyolsi
South-korea
Germany
Ukraine
United-states
Russia
Texas
Mannheim
Baden-wüberg
Chicago
Illinois
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.